Gaviscon 500mg chewable tablets peppermint

Valsts: Lielbritānija

Valoda: angļu

Klimata pārmaiņas: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktīvā sastāvdaļa:

Sodium bicarbonate; Alginic acid; Aluminium hydroxide gel dried; Magnesium trisilicate

Pieejams no:

Reckitt Benckiser Healthcare (UK) Ltd

ATĶ kods:

A02BX

SNN (starptautisko nepatentēto nosaukumu):

Sodium bicarbonate; Alginic acid; Aluminium hydroxide gel dried; Magnesium trisilicate

Deva:

170mg ; 500mg ; 100mg ; 25mg

Zāļu forma:

Chewable tablet

Ievadīšanas:

Oral

Klase:

No Controlled Drug Status

Receptes veids:

Never Valid To Prescribe As A VMP

Produktu pārskats:

BNF: 01010201

Produkta apraksts

OBJECT 1
GAVISCON PEPPERMINT FLAVOUR TABLETS
Summary of Product Characteristics Updated 14-Mar-2016 | Reckitt
Benckiser Healthcare (UK) Ltd
1. Name of the medicinal product
Gaviscon Peppermint Flavour Tablets.
2. Qualitative and quantitative composition
Each tablet contains sodium alginate 250 mg, sodium hydrogen carbonate
133.5 mg and calcium
carbonate 80 mg.
Excipients: Aspartame (E951) 3.75 mg per tablet.
For excipients, see Section 6.1.
3. Pharmaceutical form
Chewable tablet.
An off-white to cream, slightly mottled tablet.
4. Clinical particulars
4.1 Therapeutic indications
Treatment of symptoms of gastro-oesophageal reflux such as acid
regurgitation, heartburn and indigestion
(related to reflux), for example, following meals or during pregnancy
or in patients with symptoms related
to reflux oesophagitis.
4.2 Posology and method of administration
For oral use, after being thoroughly chewed.
Adults and children 12 years and over: Two to four tablets after meals
and at bedtime.
Elderly: No dose modifications necessary for this age group.
4.3 Contraindications
This medicinal product is contraindicated in patients with known or
suspected hypersensitivity to the
active substances or to any of the excipients.
4.4 Special warnings and precautions for use
If symptoms do not improve after seven days, the clinical situation
should be reviewed.
The sodium content of a four-tablet dose is 246 mg (10.6 mmol). This
should be taken into account when
a highly restricted salt diet is recommended. e.g. in some cases of
congestive cardiac failure and renal
impairment.
Each four-tablet dose contains 320 mg (3.2 mmol) of calcium carbonate.
Care needs to be taken in
treating patients with hypercalcaemia, nephrocalcinosis and recurrent
calcium containing renal calculi.
Due to its aspartame content this product should not be given to
patients with phenylketonuria.
4.5 Interaction with other medicinal products and other forms of
interaction
A time-interval of 2 hours should be considered between Gaviscon
intake and the administration